Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Local governments commonly share single service providers, making many vulnerable at once. On top of this, ransomware has often been used to mask more targeted, malicious...Technologyread more
Salesforce released its first earnings report since its $15.3 billion acquisition of Tableau Software, the company's largest deal ever.Technologyread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Kudlow also said that he still expected Chinese negotiators to meet with Trump administration officials in Washington in September to continue trade talks.Politicsread more
VMware is following through on its proposal to buy Pivotal, a fellow Dell subsidiary, and expanding into cybersecurity with the acquisition of Carbon Black.Technologyread more
Google says it shut down hundreds of YouTube channels tied to misinformation around the Hong Kong protests.Technologyread more
It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
Investors are rushing to get a piece of its privately held rival Impossible Foods before it goes public, according to the Wall Street Journal.Food & Beverageread more
Weisler has been CEO at the company since 2015 when it split from HPE.Technologyread more
Apple CEO Tim Cook has found the "recipe" for a positive relationship with the president, management expert Jeffrey Sonnenfeld told CNBC on Thursday.Politicsread more
Valeant Pharmaceuticals reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye-care business, and the Canadian drugmaker maintained its full-year adjusted earnings forecast.
The company's U.S.-listed shares were up 16 percent in premarket trading on Tuesday.
Valeant maintained its forecast for full-year adjusted earnings before interest, taxes, depreciation, and amortization of $3.60 billion to $3.75 billion, even as it divests assets to reduce its debt pile, accumulated during former CEO Michael Pearson's deal-making spree.
The company said on Tuesday it reduced total debt by about $6 billion between the end of the first quarter of 2016 and Nov. 7. The company said total long-term debt, net of unamortized discounts and issuance costs, stood at $27.14 billion.
Laval, Quebec-based Valeant also said it had eliminated all long-term debt maturities until 2020 and all mandatory amortization requirements.
"Valeant is a very different company today than it was a year ago ... We realize there is more progress to be made," Chief Executive Joseph Papa said in a statement.
The company has been rebuilding its business after coming under fire for its steep drug price hikes and the unorthodox use of a specialty pharmacy to boost sales.
Net income attributable to Valeant was $1.30 billion, or $3.69 per share, in the third quarter ended Sept. 30, compared with a loss of $1.22 billion, or $3.49 per share, a year earlier.
The reported quarter included a tax benefit of about $1.4 billion, the company said.
Excluding items, the company earned $1.04 per share, according to Thomson Reuters I/B/E/S calculation, above analysts' average estimate of 88 cents.
Total revenue fell 10.5 percent to $2.22 billion, largely due to volume decreases in its U.S. diversified products and branded businesses, but beat the estimate of $2.15 billion.
Valeant's U.S. shares are down 17 percent this year.